Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry
- PMID: 22291085
- DOI: 10.1200/JCO.2011.36.2574
Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry
Abstract
Purpose: We examined borderline estrogen receptor (ER) -positive cancers, defined as having 1% to 10% positivity by immunohistochemistry (IHC), to determine whether they show the same global gene-expression pattern and high ESR1 mRNA expression as ER-positive cancers or if they are more similar to ER-negative cancers.
Patients and methods: ER status was determined by IHC in 465 primary breast cancers and with the Affymetrix U133A gene chip. We compared expressions of ESR1 mRNA and a 106 probe set ER-associated gene signature score between ER-negative (n = 183), 1% to 9% (n = 25), 10% (n = 6), and more than 10% (n = 251) ER-positive cancers. We also assessed the molecular class by using the PAM50 classifier and plotted survival by ER status.
Results: Among the 1% to 9%, 10%, and more than 10% ER IHC-positive patients, 24%, 67%, and 92% were also positive by ESR1 mRNA expression. The average ESR1 expression was significantly higher in the ≥ 10% ER-positive cohorts compared with the 1% to 9% or ER-negative cohort. The average ER gene signature scores were similar for the ER-negative and 1% to 9% IHC-positive patients and were significantly lower than in ≥ 10% ER-positive patients. Among the 1% to 9% ER-positive patients, 8% were luminal B and 48% were basal-like; among the 10% ER-positive patients, 50% were luminal. The overall survival rate of 1% to 9% ER-positive patients with cancer was between those of patients in the ≥ 10% ER-positive and ER-negative groups.
Conclusion: A minority of the 1% to 9% IHC ER-positive tumors show molecular features similar to those of ER-positive, potentially endocrine-sensitive tumors, whereas most show ER-negative, basal-like molecular characteristics. The safest clinical approach may be to use both adjuvant endocrine therapy and chemotherapy in this rare subset of patients.
Comment in
-
Lost in translation? Estrogen receptor status and endocrine responsiveness in breast cancer.J Clin Oncol. 2012 Mar 1;30(7):686-9. doi: 10.1200/JCO.2011.38.9619. Epub 2012 Jan 30. J Clin Oncol. 2012. PMID: 22291083 No abstract available.
-
Low-estrogen receptor-positive breast cancer: the impact of tissue sampling, choice of antibody, and molecular subtyping.J Clin Oncol. 2012 Aug 10;30(23):2929-30; author reply 2931. doi: 10.1200/JCO.2012.43.2831. Epub 2012 Jul 2. J Clin Oncol. 2012. PMID: 22753914 No abstract available.
Similar articles
-
Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers.Breast Cancer Res Treat. 2014 Jan;143(2):403-9. doi: 10.1007/s10549-013-2763-z. Epub 2013 Dec 15. Breast Cancer Res Treat. 2014. PMID: 24337596
-
Multimodal Assessment of Estrogen Receptor mRNA Profiles to Quantify Estrogen Pathway Activity in Breast Tumors.Clin Breast Cancer. 2017 Apr;17(2):139-153. doi: 10.1016/j.clbc.2016.09.001. Epub 2016 Sep 13. Clin Breast Cancer. 2017. PMID: 27756582
-
Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.JAMA Oncol. 2016 Aug 1;2(8):1040-7. doi: 10.1001/jamaoncol.2016.0339. JAMA Oncol. 2016. PMID: 27100299
-
The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.Biochim Biophys Acta Rev Cancer. 2019 Dec;1872(2):188315. doi: 10.1016/j.bbcan.2019.188315. Epub 2019 Oct 21. Biochim Biophys Acta Rev Cancer. 2019. PMID: 31647985 Review.
-
Clinical implication of low estrogen receptor (ER-low) expression in breast cancer.Front Endocrinol (Lausanne). 2022 Nov 24;13:1015388. doi: 10.3389/fendo.2022.1015388. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36506043 Free PMC article. Review.
Cited by
-
Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study.Breast Cancer Res. 2022 Sep 12;24(1):61. doi: 10.1186/s13058-022-01556-6. Breast Cancer Res. 2022. PMID: 36096872 Free PMC article.
-
Comparison of neoadjuvant chemotherapy response and prognosis among pegylated liposomal doxorubicin, epirubicin and pirarubicin in HR ⩽ 10%/HER2-negative breast cancer: an exploratory real-world multicentre cohort study.Ther Adv Med Oncol. 2024 Sep 23;16:17588359241279695. doi: 10.1177/17588359241279695. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 39346118 Free PMC article.
-
Estrogen-Receptor-Low-Positive Breast Cancer: Pathological and Clinical Perspectives.Curr Oncol. 2023 Nov 4;30(11):9734-9745. doi: 10.3390/curroncol30110706. Curr Oncol. 2023. PMID: 37999126 Free PMC article. Review.
-
The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification.J Gynecol Oncol. 2019 Jan;30(1):e13. doi: 10.3802/jgo.2019.30.e13. Epub 2018 Oct 29. J Gynecol Oncol. 2019. PMID: 30479097 Free PMC article.
-
Estrogen receptor variants in ER-positive basal-type breast cancers responding to therapy like ER-negative breast cancers.NPJ Breast Cancer. 2019 Apr 18;5:15. doi: 10.1038/s41523-019-0109-7. eCollection 2019. NPJ Breast Cancer. 2019. PMID: 31016233 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous